Nona Biosciences Partners with PharmaEssentia for Nona's Harbour Mice fully human antibody transgenic mice platform

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited dedicated to cutting-edge technology innovation and a provider of integrated solutions from "Idea to IND" (I to ITM), announced a strategic collaboration agreement with Massachusetts-based PharmaEssentia Innovation Research Centre (PIRC) based on Nona's proprietary Harbour Mice fully human antibody transgenic mice platform.

"We are pleased to enter this strategic collaboration with PharmaEssentia," Nona Biosciences chairman Jingsong Wang, M.D., PhD, said. "PharmaEssentia's therapeutic solutions reflect its motivation for reshaping the treatment path for progressive cancers, and we believe that by leveraging Nona's antibody discovery ability, we can accelerate the R&D process of novel therapies." "We are delighted to partner with Nona Biosciences as we continue to expand our research capabilities and technical expertise at our newly established PIRC," said Lih-Ling Lin PhD, PharmaEssentia's chief scientific officer.

"As we assemble our team of scientists and complete the build-out of our new lab space this year, we look forward to expanding our footprint in the Boston area." Nona Biosciences (a wholly-owned subsidiary of HBM Holdings) is a global biotechnology company committed to cutting edge technology innovation, and providing a total solution from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice platforms and the experienced therapeutic antibody discovery team.